Farmakoterapia w Psychiatrii i Neurologii
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
2/2024
vol. 40
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł przeglądowy

Porównanie działania przeciwdepresyjnego esketaminy i arketaminy w terapii depresji lekoopornej – przegląd doniesień

Kamila Czora-Poczwardowska
1
,
Radosław Kujawski
1
,
Justyna Jaworska
1
,
Przemysław Mikołajczak
1
,
Michał Szulc
1

  1. Department of Pharmacology, Poznan University of Medical Sciences; Katedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (2), 127–142
DOI: https://doi.org/10.5114/fpn.2024.147494
Data publikacji online: 2025/03/31
Plik artykułu:
- 5F0_IPiN_FARM_2024-2C.pdf  [0.34 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 1983 Jun; 79 (2): 565–575.
2. Bartova L, Papageorgiou K, Milenkovic I, Dold M, Weidenauer A, Willeit M, et al. Rapid antidepressant effect of S-ketamine in schizophrenia. Eur. Neuropsychopharmacol. 2018 Aug; 28 (8): 980–982.
3. Borbély É, Simon M, Fuchs E, Wiborg O, Czéh B, Helyes Z. Novel drug developmental strategies for treatment-resistant depression. Br. J. Pharmacol. 2022 Mar; 179 (6): 1146–1186.
4. Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, et al. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. Int. J. Mol. Sci. 2021 Dec 2; 22 (23).
5. Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, et al. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs. 2023 Aug 9; 37 (8): 715–723.
6. Chang L, Zhang K, Pu Y, Qu Y, Wang S-M, Xiong Z, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol. Biochem. Behav. 2019 Jun; 181: 53–59.
7. Chen X, Hou X, Bai D, Lane R, Zhang C, Canuso C, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. Neuropsychiatr. Dis. Treat. 2023 Mar 31; 19: 693–707.
8. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Feb 1; 75 (2): 139–148.
9. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry. 2010 Dec 1; 71 (12):1605–1611.
10. Domino EF. History and pharmacology of PCP and PCP-related analogs. J. Psychedelic Drugs. 1980 Dec; 12 (3–4): 223–227.
11. European Medicines Agency (EMA). Spravato [Internet]. 2019 [cited 2024 May 8]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spravato.
12. Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int. J. Neuropsychopharmacol. 2019 Oct 1; 22 (10): 616–630.
13. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin. Pharmacokinet. 1995 Sep; 29 (3): 172–191.
14. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J-I, Hashimoto K, et al. Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. J. Pharmacol. Exp. Ther. 2017 Apr; 361 (1): 9–16.
15. Fu D-J, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J. Clin. Psychiatry. 2020 May 12; 81 (3).
16. Gałecki P, Samochowiec J, Mikułowska M, Szulc A. Treatment-Resistant Depression in Poland-Epidemiology and Treatment. J. Clin. Med. 2022 Jan 18; 11 (3).
17. Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ. GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions. J. Clin. Invest. 2020 Mar 2; 130 (3): 1336–1349.
18. Grasso V, Gutierrez G, Alzbeidi N, Hernandorena C, Vázquez GH. Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Dec 20; 135: 111095.
19. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth. Prog. 1992; 39 (3): 61–68.
20. Janssen Pharmaceutica NV. Summary of product characteristics – Spravato [Internet]. 2019 [cited 2024 May 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf.
21. Jamieson C, Popova V, Daly E, Cooper K, Drevets WC, Rozjabek HM, et al. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Health and Quality of Life Outcomes. 2023 May 8; 21 (1).
22. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wydanie III. VM Media Group Sp. z o.o. (Grupa Via Medica), 2022; p. 55–88.
23. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. J Psychopharmacol (Oxford). 2021 Feb; 35 (2): 109–123.
24. Kawczak P, Feszak I, Bączek T. Ketamine, esketamine, and arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms. Biomedicines. 2024 Oct 9; 12 (10).
25. Kim J-W, Suzuki K, Kavalali ET, Monteggia LM. Ketamine: mechanisms and relevance to treatment of depression. Annu. Rev. Med. 2024 Jan 29; 75: 129–143.
26. Kolar D. Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatr. Dis. Treat. 2018 Jun 12; 14: 1513–1519.
27. Krystal JH, D’Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl). 1999 Jul; 145 (2): 193–204.
28. Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024 Jan; 49 (1): 41–50.
29. Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur. Arch. Psychiatry Clin. Neurosci. 2021 Apr; 271 (3): 577–582.
30. Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, et al. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. J. Affect. Disord. 2023 Jun 1; 330: 7–15.
31. Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, et al. The abuse liability of ketamine: A scoping review of preclinical and clinical studies. J. Psychiatr. Res. 2022 Jul; 151: 476–496.
32. Lin P-Y, Ma ZZ, Mahgoub M, Kavalali ET, Monteggia LM. A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action. Cell Rep. 2021 Aug 17; 36 (7): 109513.
33. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010 Aug 20; 329 (5994): 959–964.
34. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct; 22 (3): 394–412.
35. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am. J. Psychiatry. 2021 May 1; 178 (5): 383–399.
36. Mihaljević S, Pavlović M, Reiner K, Ćaćić M. Therapeutic mechanisms of ketamine. Psychiatr. Danub. 2020; 32 (3–4): 325–333.
37. Morrison RL, Fedgchin M, Singh J, Van Gerven J, Zuiker R, Lim KS. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2018 Apr; 235 (4): 1107–1119.
38. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007 Mar 24; 369 (9566): 1047–1053.
39. Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Am. J. Geriatr. Psychiatry. 2020 Feb; 28 (2): 121–141.
40. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997 Apr; 86 (4): 903–917.
41. Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am. J. Psychiatry. 2019 Jun 1; 176 (6): 428–438.
42. Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R. Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Mol. Psychiatry. 2021 Sep; 26 (9): 5097–5111.
43. Rybakowski JK. Lithium treatment in the era of personalized medicine. Drug Dev. Res. 2021 Aug; 82 (5): 621–627.
44. Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. Depress. Anxiety. 2016 Aug; 33 (8): 718–727.
45. Schatzberg AF. A word to the wise about intranasal esketamine. Am. J. Psychiatry. 2019 Jun 1; 176 (6): 422–424.
46. Scott F, Hampsey E, Gnanapragasam S, Carter B, Marwood L, Taylor RW, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol (Oxford). 2023 Mar; 37 (3): 268–278.
47. Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, et al. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J. Clin. Psychiatry. 2023 Feb 1; 84 (2).
48. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol. Psychiatry. 2016 Sep 15; 80 (6): 424–431.
49. Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Spijker J, van der Meij A, van Asselt ADI, et al. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Mol. Psychiatry. 2024 Sep; 29 (9): 2657–2665.
50. Swainson J, Thomas RK, Archer S, Chrenek C, MacKay M-A, Baker G, et al. Esketamine for treatment resistant depression. Expert Rev. Neurother. 2019 Oct; 19 (10): 899–911.
51. Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021 Oct 25; 21 (1): 526.
52. The U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic [Internet]. 2019 [cited 2024 Apr 18]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified.
53. Tucker C, Tucker L, Brown K. The intranasal route as an alternative method of medication administration. Crit. Care Nurse. 2018 Oct; 38 (5): 26–31.
54. Vasiliu O. Esketamine for treatment‑resistant depression: A review of clinical evidence (Review). Exp. Ther. Med. 2023 Mar; 25 (3): 111.
55. Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J. Clin. Psychiatry. 2020 Apr 28; 81 (3).
56. Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. J. Clin. Psychiatry. 2018 Jul 24; 79 (4).
57. Włodarczyk A, Słupski J, Szarmach J, Cubała WJ. Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration. Asian J. Psychiatr. 2024 Jun; 96: 104016.
58. Yang C, Shirayama Y, Zhang J, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry. 2015 Sep 1 ;5 (9): e632.
59. Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl. Psychiatry. 2019 Nov 7; 9 (1): 280.
60. Yao W, Cao Q, Luo S, He L, Yang C, Chen J, et al. Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol. Psychiatry. 2022 Mar; 27 (3): 1618–1629.
61. Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023 Jul; 48 (8): 1225–1233.
62. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry. 2006 Aug; 63 (8) :856–864.
63. Zhang J-C, Li S-X, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol. Biochem. Behav. 2014 Jan; 116: 137–141.
64. Zhang J-C, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology. 2022 Nov 1; 218: 109219.
65. Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, et al. Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl. Psychiatry. 2020 Jan 27; 10 (1): 32.
66. Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, et al. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. Int. J. Neuropsychopharmacol. 2015 May 25; 18 (11): pyv060.

Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Czasopisma Aktualności Książki eBooki Konferencje i webinary
Serwisy
Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć KONGRES TOP MEDICAL TRENDS
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń
© 2025 Termedia Sp. z o.o.
Developed by Bentus.